Stage III Adult Soft Tissue Sarcoma Clinical Trial
Official title:
A Prospective One-arm Study of Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma
A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for neoadjuvant treatment of locally advanced soft tissue sarcoma.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients with soft tissue sarcoma confirmed by histopathology; 2. Patients with soft tissue sarcoma judged to be stage IIB/III according to the AJCC staging of soft tissue sarcoma, or tumors that are closely related to important blood vessels and important nerves suggested by imaging data; 3. No distant transfer 4. According to the preliminary judgment of the research, patients who can improve the effect of surgery by neoadjuvant treatment; 5. Male or female, aged =14 years old and =75 years old; 6. ECOG score = 2; 7. The expected survival period is =3 months; 8. Adequate hematopoietic function: absolute neutrophil count (ANC) = 1.5×109/L and platelet count = 80×109/L and hemoglobin = 9 g/dL; 9. Sufficient liver function: total bilirubin = upper limit of normal (ULN); AST and ALT = 1.5 times the upper limit of normal (ULN); alkaline phosphatase = 5 times the upper limit of normal (ULN); 10. Adequate renal function: serum creatinine = upper limit of normal (ULN) or calculated creatinine clearance = 60 mL/min; 11. Visceral function: LVEF=50%, the New York Society of Visceral Disease Association (NYHA) has a functional classification of I and II, and there is no unhealed wound on the body; 12. Sign the informed consent form. 13. Women should agree to use contraceptive measures (such as intrauterine device (IUD), contraceptives or condoms) during the study period and within 6 months after the end of the study; serum or urine pregnancy within 7 days before study entry The test is negative and must be a non-lactating patient; men should agree to patients who must use contraception during the study period and within 6 months after the end of the study period. 14. The patient voluntarily joined the study, signed an informed consent form, had good compliance, and was able to be followed up by the trial staff. Exclusion Criteria: 1. Ewing's sarcoma, embryonic rhabdomyosarcoma, acinar rhabdomyosarcoma 2. Pregnant or breastfeeding women, or women who are fertile but have not taken contraceptive measures 3. Existing severe acute infection that has not been controlled; or having purulent or chronic infection, and the wound is protracted 4. Active hepatitis B or C 5. Have a history of other tumors within 5 years before treatment, except for cured cervical carcinoma in situ or skin basal cell carcinoma 6. Those who have participated in other drug clinical trials within 4 weeks 7. Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease and refractory hypertension, ventricular tachycardia, ventricular, Patients with atrial fibrillation, second-degree type II or third-degree atrioventricular block, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease requiring medication 8. People with uncontrollable neurological or mental diseases or mental disorders, poor compliance, unable to cooperate and describe the treatment response; primary brain tumors or central nerve metastases have not been controlled, and have obvious intracranial hypertension or neuropsychiatry Symptoms 9. Past severe chronic skin diseases 10. People with bleeding tendency, evidence of hereditary bleeding constitution or coagulopathy 11. Have a clear history of allergy to chemotherapy drugs |
Country | Name | City | State |
---|---|---|---|
China | Fudan University Shanghai Cancer Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Yong Chen |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ORR | Objective Response Rate | At the end of Cycle 3 (each cycle is 21 days) | |
Secondary | pCR rate | Pathological complete response rate | One year after the first intravenous drip | |
Secondary | PFS | Progression free survival | 6 weeks after the first intravenous drip | |
Secondary | OS | Overall Survival | After the first intravenous drip,an average of 3 year through study completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00245102 -
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
|
Phase 2 | |
Completed |
NCT00003958 -
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
|
Phase 3 | |
Completed |
NCT01719302 -
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01206140 -
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01462630 -
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
|
Phase 2 | |
Completed |
NCT01016015 -
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
|
Phase 2 | |
Completed |
NCT02180698 -
TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01782313 -
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|
Phase 2 | |
Terminated |
NCT00233948 -
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00937495 -
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00720174 -
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
Completed |
NCT00087074 -
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00064324 -
Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Terminated |
NCT00022542 -
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT02048722 -
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
|
Phase 2 | |
Withdrawn |
NCT03613259 -
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
|
Early Phase 1 |